My Notes

There are 600 + physicians and other health care providers practicing within 18 different clinical entities, or specialty groups that are affiliated with Stony Brook University Physicians (SBU Physicians). Together, these providers offer patients of all ages a comprehensive range of high quality medical services, from primary care to advanced specialty care. The physicians and health care professionals affiliated with SBU Physicians are committed to excellence in service and leadership in clinical care. In their capacity as faculty of the Stony Brook University School of Medicine, they also educate medical students, interns, residents and fellows in many specialties and sub-specialties, and engage in research and clinical trials that help to advance the science of medicine.

My Articles

1. Ocean AJ, Schnoll-Sussman F, Chen XE, Keresztes R, Holloway S, Matthews N, O'Brien K, Christos P, Mazumdar M, Wadler S. "Recent results of phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA)" 2007 Gastrointestinal Cancers Symposium (abstr 45).

2. Lilenbaum R, Socinski MA, Altorki NK, Hart LL, Keresztes RS, Hariharan S, Morrison ME, Fayyad R, Bonomi P. "Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small cell lung cancer." J Clin Oncol 2006; 24(30):4825-4832.

3. Ocean AJ, Schnoll-Sussman F, Keresztes R, Chen X, Holloway S, Matthews N, Christos P, Mazumdar M, Wright J, Wadler S. "Phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA)." Proc ASCO 2006; 24 (abstr 14040).

4. Port JL, Korst RJ, Lee PC, Levin MA, Becker DE, Keresztes R, Altorki NK, "Surgical resection for residual N2 disease after induction chemotherapy." Ann Thorac Surg 2005; 79:1686-1690.

5. Altorki NK, Port JL, Korst RJ, Keresztes RS, "A phase II trial of preoperative paclitaxel/carboplatin with celecoxib followed by adjuvant celecoxib for esophageal cancer: preliminary report." Proc ASCO 2005: 24 (abstr 4205).

6. Keresztes RS, Socinski M, Bonomi P, Chen A, Hart R, Lilenbaum R. "Phase II Randomized Trial of Irinotecan/Docetaxel (ID) or Irinotecan/Gemcitabine (IG) With or Without Celecoxib (CBX) in 2nd-Line Treatment of Non-Small Cell Lung Cancer." Proc ASCO 2004; 23:647 (abstr 7137).

7. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L, "Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients with metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342." J Clin Oncol 2004; 22(11):2061-2068.

8. Port JL, Kent MS, Korst RJ, Keresztes R, Levin MA, Altorki NK, "Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer." Ann Thorac Surg 2004;77(1):254-259.

9. Keresztes RS, Port JL, Pasmantier MW, Korst RJ, Altorki NK, "Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: Results of a Phase II Trial." J Thorac Cardiovasc Surg 2003;126(5):1603-1608.